FDA expands approval for Zoryve cream 0.3% to children with psoriasis as young as 2 years

The FDA approved Zoryve cream 0.3% for the treatment of plaque psoriasis in children as young as 2 years, Arcutis announced in a press release. Roflumilast (Zoryve, Arcutis) cream 0.3%, a phosphodiesterase-4 inhibitor, is already FDA-approved for children 6 years and older. The expanded indication gives caregivers a once-daily, steroid-free topical for younger children with psoriasis, including